Advanced searches left 3/3

Multiple Sclerosis - Springer Nature

Summarized by Plex Scholar
Last Updated: 13 September 2022

* If you want to update the article please login/register

COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients

Objectives: Objective To determine the effectiveness of preventive high-dose corticosteroids in the post-partum period by comparing two approaches: no preventive therapy and standardized preventive therapy. Methods We selected five French Multiple Sclerosis centers based on the same post-partum program for their patients—either high-dose steroids or no therapy — both have been developed. Conclusions This review provides class III evidence that systemic high-dose corticosteroids are not linked to reduced inflammation activity during the post-partum period in multiple sclerosis patients.

Source link: https://doi.org/10.1007/s00415-022-11215-7


Graves’ disease induced by Alemtuzumab in relapsing–remitting multiple sclerosis patients: an observational study in a reference center

Objectives Graves U2019 disease caused by Alemtuzumab is one of the most common adverse events in patients with multiple sclerosis treated with Alemtuzumab. Materials and methods We conducted a retrospective observational study identifying patients with relapsing multiple sclerosis and GD-IA, determining their baseline clinical characteristics and variables related to the disease's natural history. A total of 70% of patients undergoing GD-IA had fluctuations in thyroid function during follow-up, and 24. 4% needed total thyroidectomy for diagnosis of the condition. The identification of risk factors for the disease before beginning treatment with Alemtuzumab and early monitoring of thyroid function after this therapy have been started have been shown to be effective methods in the diagnosis and clinical management of this disease.

Source link: https://doi.org/10.1007/s40618-022-01832-4


Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion

By blocking the development of disability-related conditions, early intervention with high-efficacy disease-modifying therapies may be the best window of opportunity to prevent irreversible central nervous system injury and MS-related disability progression. In terms of increased inflammatory function and neurodegeneration, in comparison to delayed HE-DMT use or increasealation strategy, early use of HE-DMTs can lead to a significant decrease not only of inflammation activity but also of disease progression, including irreversible clinical illness and neurodegeneration. According to prognostic factors indicating aggressive disease, disease occurrence, clinical and/or radiologic involvement, and patient-related factors, such as potential comorbidities, family planning, and patients with MS early after diagnosis, it should be advisable to monitor MS patients early in the course of diagnosis, including potential comorbidities, family planning, and patients with MS. According to the EAN/ECTRIMS and AAN guidelines, it should be expected to treat MS patients early after diagnosis.

Source link: https://doi.org/10.1007/s00415-022-11193-w


Combination effects of mesenchymal stem cells transplantation and anodal transcranial direct current stimulation on a cuprizone-induced mouse model of multiple sclerosis

In comparison to the CPZ mice, the tDCS and CPZ + MSCs mice showed significant improvement in motor coordination and balance in CPZ+ tDCS and CPZ+ MSCs mice's motor coordination and balance capabilities. Compared to the CPZ mice, tDCS and MSCs mice with tDCS and MSCs staining demonstrated that transplantation of tDCS and MSCs mice could enhance remyelination capacity in CPZ+ tDCS and CPZ + MSCs mice. However, the effect of tDCS transplantation on the remyelination process was larger than that of simple therapy. The numbers of Olig2+ cells in CPZ + tDCS and MSCs mice increased by tDCS and MSCs transplantation in CPZ + CPZ + MSCs mice, relative to the CPZ mice, according to the CPZ mice. In comparison to the CPZ mice, MSCs transplantation significantly reduced the TUNEL+ cells in CPZ + MSCs and CPZ + MSCs mice, as well as the CPZ mice.

Source link: https://doi.org/10.1007/s10735-022-10092-8


Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis

This cross-sectional report looked at whether aerobic fitness was differentially related to cognitive processing speed and walking endurance in MS people with MS who have MS who live with and without TA. Methods 44 fully ambulatory people with MS completed a graded exercise test for measuring aerobic endurance and underwent 3T MRI for measuring TA, the Symbol Digit Modalities Test, and the 6-minute walk. In the TA group, the inverse correlations between V O_2peak and SDMT, as well as V O_2peak and 6MW, were much stronger. Such results point to TA as a moderator of the relationship between aerobic fitness, cognitive processing speed, and walking endurance in MS patients with MS. Future research should consider the role of TA in designing trials of aerobic exercise, cognition, and mobility in MS.

Source link: https://doi.org/10.1007/s00415-022-11205-9


Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis

Background Ocrelizumab has been shown to reduce brain atrophy in primary progressive multiple sclerosis patients, but no studies are currently available on the effect of ocrelizumab on retinal layer thicknesses in the PPMS population. In ocrelizumab-treated PPMS, retinal layer changes are observed and tested for potential use as biomarkers of therapy response, with therapy reactions. In PPMS, the thickness of the retinal nerve fiber layer, macular ganglion cell, and inner retinal layer volume were all significantly lower than those of HC. Conclusions Ocrelizumab significantly reduces the INL thinning rate in PPMS responders, which is much lower than previously expected.

Source link: https://doi.org/10.1007/s00415-022-11183-y


Early use of fingolimod is associated with better clinical outcomes in relapsing–remitting multiple sclerosis patients

Background Multiple sclerosis is a chronic autoimmune disease with a wide range of medical, disease occurrence, and treatment responses. The present observational study seeks to determine patients who might benefit from this therapy, stratifying them according to the disease-modifying drugs used before FTY to identify patients who might benefit from this therapy. Methods We prospectively included 554 RRMS patients who started FTY at San Raffaele Hospital between 2012 and 2018. Despite a higher rate of baseline disease activity, the percentage of patients who maintained NEDA-3 status in the na00efve group remained higher in the nau00efve group. Conclusion Nau00eftive patients had a greater response to FTY than those who switched to FTY from other drugs. Our results support the early use of FTY in patients with active MS.

Source link: https://doi.org/10.1007/s00415-022-11227-3


Fampridine in multiple sclerosis patients with acute phase of cervical transverse myelitis: a double-blind, randomized placebo-controlled trial

Background Fampridine is a potassium channel blocker that is used to improve walking performance in patients with multiple sclerosis. In patients with MS who had acute form of transverse myelitis, we investigated the effects of fampridine in patients with MS. Methods In a random, placebo-controlled trial, 30 patients with their first episode of cervical myelitis with quadriparesis presentation, with the final diagnosis of MS, were randomly divided into two equal groups. For 7 days plus placebo, the placebo group received IVMP. To compare the treatment findings, we compared the Barthel index scores of the groups at the start of the trial and the 21st day after the start of therapy. Conclusion Using fampridine plus IVMP in MS patients' acute phase of transverse myelitis improved the disease's symptoms and improved patients' daily activities ability.

Source link: https://doi.org/10.1007/s10072-022-06380-6

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions